Quick Answer
Intellia Therapeutics, Inc. reported Net Income Loss of -$412.69 million for the year ending 2025.
- Intellia Therapeutics, Inc. showed an increase of +20.5% in Net Income Loss from 2024 to 2025.
- This data is from Intellia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$6.69 million | Q2 2016: -$6.90 million | Q3 2016: -$7.48 million | Q4 2016: -$10.56 million | Q1 2017: -$12.63 million | Q2 2017: -$15.59 million | Q3 2017: -$15.36 million | Q4 2017: -$23.96 million | Q1 2018: -$21.36 million | Q2 2018: -$22.22 million | Q3 2018: -$22.70 million | Q4 2018: -$19.07 million | Q1 2019: -$21.94 million | Q2 2019: -$25.68 million | Q3 2019: -$23.63 million | Q4 2019: -$28.28 million | Q1 2020: -$31.81 million | Q2 2020: -$32.39 million | Q3 2020: -$27.84 million | Q4 2020: -$42.19 million | Q1 2021: -$46.21 million | Q2 2021: -$68.81 million | Q3 2021: -$71.64 million | Q1 2022: -$146.87 million | Q2 2022: -$100.68 million | Q3 2022: -$113.23 million | Q1 2023: -$103.13 million | Q2 2023: -$123.68 million | Q3 2023: -$122.22 million | Q1 2024: -$107.44 million | Q2 2024: -$146.98 million | Q3 2024: -$135.71 million | Q1 2025: -$114.33 million | Q2 2025: -$101.26 million | Q3 2025: -$101.32 million.
- Over the full 11 years of available data (2015 to 2025), Intellia Therapeutics, Inc.'s Net Income Loss has declined by 3,229.0%.
- Historical annual values: Fiscal year 2025: -$412.69 million | Fiscal year 2024: -$519.02 million | Fiscal year 2023: -$481.19 million | Fiscal year 2022: -$474.19 million | Fiscal year 2021: -$267.89 million | Fiscal year 2020: -$134.23 million | Fiscal year 2019: -$474.19 million | Fiscal year 2018: -$85.34 million | Fiscal year 2017: -$67.54 million | Fiscal year 2016: -$31.63 million | Fiscal year 2015: -$12.40 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: